loading
전일 마감가:
$4.88
열려 있는:
$4.88
하루 거래량:
32,619
Relative Volume:
0.00
시가총액:
$15.16M
수익:
-
순이익/손실:
$-37.75M
주가수익비율:
-1.4646
EPS:
-3.25
순현금흐름:
$-30.91M
1주 성능:
+1.60%
1개월 성능:
-6.19%
6개월 성능:
+1,616%
1년 성능:
+125.24%
1일 변동 폭
Value
$4.72
$4.88
1주일 범위
Value
$4.11
$4.89
52주 변동 폭
Value
$0.224
$10.19

Cellectar Biosciences Inc Stock (CLRB) Company Profile

Name
명칭
Cellectar Biosciences Inc
Name
전화
(608) 441-8120
Name
주소
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Name
직원
11
Name
트위터
@CellectarBio
Name
다음 수익 날짜
2025-03-05
Name
최신 SEC 제출 서류
Name
CLRB's Discussions on Twitter

CLRB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CLRB
Cellectar Biosciences Inc
4.7502 13.43M 0 -37.75M -30.91M -3.25
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.48 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.52 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
452.21 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
693.90 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
316.06 37.96B 3.81B -644.79M -669.77M -6.24

Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-05 재개 Ladenburg Thalmann Buy
2020-07-01 개시 Oppenheimer Outperform
2020-01-21 재개 ROTH Capital Buy
2019-09-13 개시 ROTH Capital Buy
2016-12-21 개시 Ladenburg Thalmann Buy

Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스

pulisher
Aug 19, 2025

What high frequency data says about Cellectar Biosciences Inc.Index Update & Community Shared Stock Ideas - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Visualizing Cellectar Biosciences Inc. stock with heatmapsTrade Signal Summary & Daily Profit Focused Stock Screening - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

What’s next for Cellectar Biosciences Inc. stock priceMarket Sentiment Report & Weekly Momentum Picks - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Using Ichimoku Cloud for Cellectar Biosciences Inc. technicals2025 AllTime Highs & Advanced Swing Trade Entry Alerts - Newser

Aug 19, 2025
pulisher
Aug 19, 2025

Does Cellectar Biosciences Inc. show high probability of rebound2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - Newser

Aug 19, 2025
pulisher
Aug 18, 2025

Using AI based signals to follow Cellectar Biosciences Inc.2025 Key Lessons & Technical Pattern Based Signals - Newser

Aug 18, 2025
pulisher
Aug 17, 2025

Will Cellectar Biosciences Inc. see short term momentumTrade Volume Summary & Weekly Top Gainers Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

XTX Topco Ltd Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

Earnings Chart Overlay Points to Cellectar Biosciences Inc. UpsideQuarterly Portfolio Review & Weekly Consistent Profit Watchlists - 선데이타임즈

Aug 17, 2025
pulisher
Aug 17, 2025

How high can Cellectar Biosciences Inc. stock go2025 Technical Patterns & Risk Managed Investment Signals - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

How sentiment analysis helps forecast Cellectar Biosciences Inc.Recession Risk & Low Drawdown Investment Ideas - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Advanced analytics toolkit walkthrough for Cellectar Biosciences Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Support Zone Holds Steady for Cellectar Biosciences Inc. After Dip2025 Winners & Losers & Daily Entry Point Trade Alerts - 선데이타임즈

Aug 16, 2025
pulisher
Aug 16, 2025

Key metrics from Cellectar Biosciences Inc.’s quarterly dataWeekly Profit Recap & Verified High Yield Trade Plans - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Oppenheimer Maintains Hold Rating on Cellectar Biosciences with $18.00 Average Price Target - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Cellectar Cuts Q2 Losses and Expenses - AOL.com

Aug 15, 2025
pulisher
Aug 15, 2025

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2025 Earnings Call Transcript - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire

Aug 15, 2025
pulisher
Aug 15, 2025

Cellectar signals NDA submission for iopofosine I-131 in WM by early 2026 amid accelerated approval focus - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Cellectar Biosciences Reports Q2 2025 Financial Results - TipRanks

Aug 15, 2025
pulisher
Aug 14, 2025

Cellectar Biosciences Reports Q2 EPS $3.39, Below Consensus $3.70 - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar Biosciences Q2 2025 Earnings Report - MarketBeat

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar Biosciences shares fall 1.81% after-hours following Q2 2025 earnings call. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar's 2025 Q2 Earnings Call: Key Contradictions in Phase 3 Trial Strategy and Cost Projections - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar to Submit NDA for Iopofosine I-131 in WM by Early 2026, Focuses on Accelerated Approval - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Earnings call transcript: SelectR Biosciences Q2 2025 reports $5.4M loss - Investing.com

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar Biosciences shares rise 7.47% premarket after reporting positive updates on Iopofosine I 131 and CLR 125. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar Achieves Q2 Loss Reduction, R&D Expenses Drop 67.1% - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar Biosciences Reports Q2 GAAP EPS of -$3.39, Beats Estimate by $0.31, with Cash and Cash Equivalents of $11M as of June 30. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar Biosciences Advances Iopofosine I 131 for WM, CLR 125 for TNBC. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar's Blood Cancer Drug Gets FDA Breakthrough Status, Eyes Accelerated Approval Path - Stock Titan

Aug 14, 2025
pulisher
Aug 14, 2025

Cellectar Biosciences, Inc. SEC 10-Q Report - TradingView

Aug 14, 2025
pulisher
Aug 13, 2025

Why Cellectar Biosciences Inc. stock attracts strong analyst attentionTrade Risk Report & Weekly Top Gainers Trade List - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Cellectar Biosciences Q2 2025 Earnings Preview: Analysts Expect $-3.66 EPS - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

How to manage a losing position in Cellectar Biosciences Inc.Weekly Earnings Recap & Weekly Return Optimization Alerts - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Published on: 2025-08-13 08:37:11 - Newser

Aug 13, 2025
pulisher
Aug 13, 2025

Cellectar Biosciences Inc. stock chart pattern explained2025 Market Overview & Long-Term Growth Portfolio Plans - Newser

Aug 13, 2025
pulisher
Aug 12, 2025

How to recover losses in Cellectar Biosciences Inc. stockSummary of Trade Cycles in 5-Year Range - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

What moving averages say about Cellectar Biosciences Inc.Free Investment Strategy With Low Risk - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Multi factor analysis applied to Cellectar Biosciences Inc.High Return Trade Roadmap with Setup Filters - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Cellectar Biosciences Inc. stock trend forecastTechnical Trend Forecast for Investors - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

What recovery options are there for Cellectar Biosciences Inc.Daily Stock Movement Forecast with Accuracy - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Cellectar Biosciences (CLRB) Expected to Announce Quarterly Earnings on Thursday - Defense World

Aug 12, 2025
pulisher
Aug 11, 2025

A | What is Cellectar Biosciences, Inc.'s revenue forecastBest ROI Stock Strategies - newsyoung.net

Aug 11, 2025
pulisher
Aug 11, 2025

Will a bounce in Cellectar Biosciences Inc. offer an exitPattern Recognition Tool for ROI Investors - Newser

Aug 11, 2025
pulisher
Aug 07, 2025

Cellectar Biosciences reports Q2 financial results, conference call on August 14. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 - Yahoo Finance

Aug 07, 2025
pulisher
Aug 05, 2025

Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc - Barchart.com

Aug 05, 2025
pulisher
Aug 05, 2025

Is Cellectar Biosciences Inc. trending in predictive chart modelsFree Smart Money Tracking Signal Generator - Newser

Aug 05, 2025
pulisher
Aug 04, 2025

Cellectar Biosciences Inc. Shows Early Signs of Technical StrengthInvestment Plan With Growth Optimization Finalized - metal.it

Aug 04, 2025

Cellectar Biosciences Inc (CLRB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Cellectar Biosciences Inc 주식 (CLRB) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Longcor Jarrod
Chief Operating Officer
Jul 02 '25
Buy
4.99
10,000
49,900
12,768
Kolean Chad J
Chief Financial Officer
Jul 02 '25
Buy
4.99
5,000
24,950
6,418
Longcor Jarrod
Chief Operating Officer
Jan 10 '25
Buy
0.28
30,000
8,400
83,141
$36.87
price up icon 1.49%
$85.11
price up icon 0.57%
$26.13
price down icon 0.27%
$109.86
price down icon 0.90%
$131.70
price down icon 0.27%
biotechnology ONC
$316.47
price up icon 0.98%
자본화:     |  볼륨(24시간):